Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01134055 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
NCT01134055: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT01134055 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 510 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01134055, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
Primary Outcome
BCVA was measured in the study eye using the ETDRS grading charts starting at a test distance of 4 meters. The ETDRS grading chart was of at least 24 to 78 letters. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. There were seven cut off points in change from baseline visual acuity on ETDRS grading chart which are, 15 to 29, 10 to 14, 5 to 9, -4 to 4, -5 t
Interventions
- DRUG placebo
- DRUG pazopanib eye drops
- BIOLOGICAL ranibizumab intravitreal injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2010-06-01 |
| Est. Completion | 2012-10-01 |
| Phase | Phase 2 |
What the finished NCT01134055 record still lists
NCT01134055 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01134055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01134055 about?
NCT01134055 is a clinical study titled "Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration". The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
What is the current status of trial NCT01134055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2010-06-01. Estimated completion is 2012-10-01.
What interventions are being tested in trial NCT01134055?
The interventions under investigation include: placebo (DRUG), pazopanib eye drops (DRUG), ranibizumab intravitreal injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT01134055?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01134055's enrollment target sits among peer trials
510 68th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI